Leadership & Pay ·
Anavex Life Sciences appoints Terrie Kellmeyer as CEO and President effective November 1, 2026
AVXLAnavex Life Sciences Corp.
The Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as Interim Chief Executive Officer since May 4, 2026, to the permanent roles of President and Chief Executive Officer. Dr. Kellmeyer also joined the Board of Directors, which concurrently reduced its size from six to five members while commencing a search for an additional independent director. Her annual base salary remains at $500,000 with an anticipated bonus of 30% of base pay. The appointment follows her tenure as Senior Vice President of Clinical Development and Strategic Advisor at the company. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases.